Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
ABVC BioPharma, Inc. - Common Stock
(NQ:
ABVC
)
0.5100
-0.0200 (-3.77%)
Streaming Delayed Price
Updated: 10:47 AM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
14,417
Open
0.5040
Bid (Size)
0.5030 (4)
Ask (Size)
0.5300 (160)
Prev. Close
0.5300
Today's Range
0.5020 - 0.5200
52wk Range
0.4053 - 2.450
Shares Outstanding
24,420,526
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 16, 2024
Via
Benzinga
Performance
YTD
-57.50%
-57.50%
1 Month
-2.30%
-2.30%
3 Month
-26.87%
-26.87%
6 Month
-32.81%
-32.81%
1 Year
-57.85%
-57.85%
More News
Read More
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 15, 2024
Via
Benzinga
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
August 15, 2024
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024
August 14, 2024
Via
InvestorPlace
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024
May 17, 2024
Via
InvestorPlace
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
July 09, 2024
Via
NewMediaWire
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
July 02, 2024
Via
NewMediaWire
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
July 02, 2024
Via
TheNewswire.com
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
June 25, 2024
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
June 12, 2024
Via
NewMediaWire
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
May 24, 2024
Via
NewMediaWire
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
May 22, 2024
Via
NewMediaWire
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
May 15, 2024
Via
NewMediaWire
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
May 09, 2024
Via
NewMediaWire
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
May 09, 2024
Via
TheNewswire.com
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
April 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 23, 2024
Via
Benzinga
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
April 18, 2024
Via
TheNewswire.com
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
April 18, 2024
Via
NewMediaWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
April 17, 2024
Via
NewMediaWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 10, 2024
Via
Benzinga
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
April 10, 2024
Via
NewMediaWire
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
April 10, 2024
Via
TheNewswire.com
12 Health Care Stocks Moving In Monday's After-Market Session
April 01, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.